SCHEMBL2177925

SCHEMBL2177925

O=[N+]([O-])c1cccnc1Nc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.69
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
L3MBTL1 Q9Y468 3/20 0.59
RAB9A P51151 4/20 0.59
NPC1 O15118 3/20 0.59
MAPK1 P28482 2/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
GSK3B P49841 2/20 0.57
ALDH1A1 P00352 4/20 0.57
CASP7 P55210 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
PIN1 Q13526 1/20 0.56
DHODH Q02127 1/20 0.53
PKM P14618 2/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27963761 0.91 MAPT (0.60) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL11435594 0.89 MAPT (0.68) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL6797321 0.87 MAPT (0.55) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL6798323 0.86 MAPT (0.54) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL5022935 0.86 MAPT (0.68) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL6791419 0.86 MAPT (0.60) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL10812183 0.86 MAPT (0.68) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL29241859 0.86 MAPT (0.68) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL2177712 0.86 MAPT (0.68) MAPTMEN1KMT2AL3MBTL1RAB9A
SCHEMBL28525161 0.86 MAPT (0.64) MAPTMEN1KMT2AL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0099614-A2 Nitro, amino and aroylamino-N-phenylpyridinamines and their use in a process for preparing pyrido(1,4)benzodiazapines A.H. ROBINS COMPANY, INCORPORATED (US) 1984-02-01 EP claimed
CN-111333615-B Heterocyclic compound and organic light-emitting device including the same 三星显示有限公司 2025-02-28 CN disclosed
CN-118027109-A Single-molecule white light iridium complex, preparation method and application thereof, and light-emitting device 清华大学深圳国际研究生院 2024-05-14 CN disclosed
EP-3189036-B1 COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS ARQULE INC (US) 2023-07-19 EP disclosed
US-11600791-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-03-07 US disclosed
EP-3936512-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS Universal Display Corporation (US) 2022-01-12 EP disclosed
EP-3424935-B1 IMIDAZOPYRAZINYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORP (US) 2021-08-11 EP disclosed
EP-3424935-B1 IMIDAZOPYRAZINYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORP (US) 2021-08-11 EP disclosed
US-20210050530-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2021-02-18 US disclosed
US-20210050530-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2021-02-18 US disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed
US-5434172-A Antitumor EISAI CO., LTD. (JP) 1995-07-18 US disclosed
US-5332751-A Antitumor EISAI CO., LTD. (JP) 1994-07-26 US disclosed
US-5292758-A Sulfonamide derivatives EISAI CO., LTD. (JP) 1994-03-08 US disclosed
US-5250549-A Antitumor agents EISAI CO., LTD. (JP) 1993-10-05 US disclosed
CN-1059519-A Sulfonamide derivatives EISAI CO LTD (JP) 1992-03-18 CN disclosed
EP-0472053-A2 Sulfonamide derivatives Eisai Co., Ltd. (JP) 1992-02-26 EP disclosed
US-4698430-A ANTIDEPRESSANT A. H. ROBINS COMPANY, INC. (US) 1987-10-06 US disclosed
US-4558132-A ANTIDEPRESSANTS A. H. ROBINS COMPANY, INCORPORATED (US) 1985-12-10 US disclosed
EP-0099614-A2 Nitro, amino and aroylamino-N-phenylpyridinamines and their use in a process for preparing pyrido(1,4)benzodiazapines A.H. ROBINS COMPANY, INCORPORATED (US) 1984-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210050530-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES NUDC, NCL, NDC1 MAPT 608/4885MEN1 2130/4885KMT2A 3120/4885
US-11600791-B2 Organic electroluminescent materials and devices NUDC, NCL, NDC1 MAPT 608/4885MEN1 2130/4885KMT2A 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.